Show simple item record

dc.contributor.authorKeyter, A
dc.contributor.authorBanoo, Shabir
dc.contributor.authorSalek, Mir-Saeed Shayegan
dc.contributor.authorWalker, Stuart R.
dc.date.accessioned2019-01-15T12:15:08Z
dc.date.available2019-01-15T12:15:08Z
dc.date.issued2018-12-04
dc.identifier.citationKeyter , A , Banoo , S , Salek , M-S S & Walker , S R 2018 , ' The South African Regulatory System: Past, Present, and Future ' , Frontiers in Pharmacology , vol. 9 , 1407 . https://doi.org/10.3389/fphar.2018.01407
dc.identifier.issn1663-9812
dc.identifier.otherPURE: 15814778
dc.identifier.otherPURE UUID: 7a47b7b2-a2f0-4310-90b7-b22ff2d9b8c6
dc.identifier.urihttp://hdl.handle.net/2299/20955
dc.description.abstractThe drive for improved regulatory systems and the establishment of a more effective regulatory framework in South Africa has been evident for the past two decades but despite political intentions and legislative revisions success has been limited to date. Efforts to address the increasing volume of applications that have been received have to date failed and resources have been stretched to capacity resulting in the development of a significant backlog and extended timelines for product registration. The promulgation of the recently amended Medicines and Related Substance Act of 1965 triggered the establishment of the South African Health Products Regulatory Authority (SAHPRA) as a separate juristic person outside of the National Department of Health to replace the former medicine regulatory authority the Medicines Control Council (MCC). The aim of this review is to provide the historical context supporting the new regulatory environment in South Africa and the transition from the MCC to SAHPRA. Key recommendations to SAHPRA to ensure the full potential of the new regulatory environment in South Africa include: establishing a quality management system to safeguard accountability, consistency and transparency and to streamline the implementation of good review practices including quality decisionmaking practices and benefit-risk assessment; the measurement and monitoring of regulatory performance, targets for overall approval time and key review milestones to instill a culture of accurate metrics collection and measurement of key performance indicators and their continuous improvement and the employment of a risk-based approach to the evaluation of medical products and codify the use of facilitated regulatory pathways in policy and culture. The application of a risk-based approach to regulatory review commensurate with a product’s risk to patients will facilitate the application of increased resources for pharmacovigilance activities and to support the reliance and recognition of reference agencies.en
dc.format.extent13
dc.language.isoeng
dc.relation.ispartofFrontiers in Pharmacology
dc.titleThe South African Regulatory System: Past, Present, and Futureen
dc.contributor.institutionPublic Health and Patient Safety Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.3389/fphar.2018.01407
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record